Kornimate/medical-research-clean huggingface dataset:
trigger finger preference elicitation tool

Conditions: Trigger Finger; Trigger Thumb; Trigger Digit; Trigger Finger Disorder; Trigger Thumb, Left Thumb; Trigger Thumb, Right Thumb; Trigger Finger, Ring Finger; Trigger Finger, Index Finger; Trigger Finger, Middle Finger; Trigger Finger, Little Finger; Trigger Thumb, Unspecified Thumb; Trigger Finger, Unspecified Finger

Summary: the purpose of this study is to evaluate a patient's level of decisional conflict for their treatment decision regarding their trigger finger, and study if the use of a preference elicitation tool at point of care is able to alter the level of decisional conflict

all patients presenting to the hand surgery clinic for evaluation of a new trigger finger will be approached for inclusion in the study. upon diagnosis, a patient diagnosed with a trigger will be informed of the study, asked if they would like to participate, and consented into the study. patients will then be randomized to a control group versus our test group. the control group will be given a generic handout about trigger finger and the treatment options. they will then complete the decisional conflict survey without using the tool. the second group will use the tool and then complete the decisional conflict survey. the standard of care is not being altered- all treatment options will still be available to patients and they have select whatever option is most in line with their preference for treatment. the purpose of the tool is to facilitate preference elicitation for treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of trigger finger exclusion criteria: * prior trigger finger treatment
confounding factors of impedance pneumography

Conditions: Healthy; Sleep Apnea

Summary: the purpose of this study is to evaluate the association of signals recorded and analysed with ventica® lung function testing system (lfts) in infants and pre-schoolers during the whole night sleep with the gold standard for sleep recording events, polysomnography, in order to better understand the confounding factors for momentary changes in the impedance pneumography-derived tidal breathing flow-volume (tbfv) curves.


Eligibility criteria:
group 1: (children referred to sleep study for clinical reasons) inclusion criteria: * age 1-7 years, both sexes * referred to polysomnography * signed informed consent group 2: (healthy children) inclusion criteria: * 2-7 years, both sexes * healthy at the time of inclusion based on history and clinical examination according to the investigator judgement * lung function in the reference range * signed informed consent exclusion criteria: * preterm birth with chronic respiratory disorder of prematurity * significant nasal congestion or adenotonsillar hypertrophy with signs and symptoms of sleep apnea or sleep disordered breathing * chronic rhinosinusitis, synonasal polyposis * personal or family history or clinical evidence of asthma, atopy or other chronic respiratory disorders (high risk for asthma and allergy) * use of asthma rescue or maintenance medication within 4 weeks prior to inclusion * recurrent bronchitis or recurrent hospitalizations because of a respiratory illness (recurrent pneumonia) * hospital-treated for bronchiolitis with residual symptoms * acute respiratory infection or hospitalization because of an acute illness within 4 weeks prior to inclusion * other cardiorespiratory or neurological chronic diseases or states that may significantly alter the overnight breathing pattern * implanted or external active medical devices * long lasting respiratory events during the polysomnography study like continuous upper airway limitation
microwave ablation in ground glass nodules

Conditions: Microwave Ablation; Lung Cancer

Summary: ggo was commonly observed recently.radiofrequency ablation has been widely applied in the treatment of patients with ggo. no study had explored the microwave ablation in the treatment of ggo.

ggo was common with the development of image. treatments of ggo include radical surgery and irradiation. for patients who were poor candidate of surgery, image guided thermal ablation could be an alternative.radiofrequency ablation has been widely applied in the treatment of eary-stage non small cell lung cancer and those patients with ggo. however, up to date, no study had explored the microwave ablation in the treatment of ggo.

Eligibility criteria:
inclusion criteria: 1. patient has a histologically verified ais or mia. 2. the tumors small enough to treat (usually ≤3 cm), and without chest pleura invasion. 3. solid cements in the ggo less than 50%. 4. no other sites of disease observed. 5. patient is not a candidate for surgical removal of the cancer, or refused surgery. 6. patient is not a candidate for radiation therapy, or refused radiation therapy. 7. patient has \> 6 month life expectancy. 8. eastern cooperative oncology group performance status of 0 to 2. 9. no prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. 10. sufficient organ functions. 11. written informed consent. exclusion criteria: 1. active bacterial or fungous infection. 2. simultaneous or metachronous (within the past 5 years) double cancers. 3. women during pregnancy or breast-feeding. 4. interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema. 5. uncontrollable diabetes mellitus. history of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.

Keywords: microwave ablation lung cancer ground glass nodules
factors affecting therapeutic efficacy of vaginal laser therapy for female stress urinary incontinence, and the effect of vaginal laser therapy on overactive bladder syndrome and sexual function

Conditions: Laser Thermotherapy, Stress Urinary Incontinence

Summary: the main aim of this study is to elucidate factors affecting treatment efficacy of vaginal laser therapy.

laser thermotherapy can increase the stiffness of vaginal wall. it has been reported that vaginal laser therapy can be used to treat stress urinary incontinence. however, factor affecting treatment efficacy of vaginal laser therapy remains unknown. thus the main aim of this study is to elucidate factors affecting treatment efficacy of vaginal laser therapy. besides, the durability of vaginal laser therapy will be assessed. the above knowledge should be helpful for clinical decision making.

Eligibility criteria:
inclusion criteria: * \>20 years old female * had stress urinary incontinence symptoms * sexual behavior * no urinary tract infection * at their own expense for vaginal laser therapy exclusion criteria: * abnormal vaginal bleeding * vaginal fistula
clinical efficacy and safety of tender point infiltration (tpi) for acute and subacute zoster associated pain

Conditions: Herpes Zoster; Local Infiltration; Acute Pain

Summary: herpes zoster (hz) is a skin infection disease which cause severe zoster-associated pain (zap) along sensory nerve in the corresponding segment. evidence for the efficacy of existing local therapies for acute/subacute zap is limited. the hypothesis is that patients with acute/subacute zap treated with tpis with local anesthetic and steroids under the basis of standard treatment will show better clinical outcomes compared with subjects treated with standard antiviral medicine treatment only.

the conventional therapies for hz infection can be seen in two phases. those in acute phase are mainly antiviral (acyclovir, famciclovir, etc.), analgesic drugs (opioids, acetaminophen or nonsteroidal anti-inflammatory agents, gabapentin, etc.), while these conventional drug therapies could yield potential side effects, and part of patients are not fully satisfied with the analgesic effect. it is considered that supplementary and alternative local therapies may have better results with less side effects and reduce medical costs to relieve pain associated with hz infection. these options, including nerve blockade (epidural injection, paravertebral injection, sympathetic block, intercostal nerve block, intracutaneous injection), pulsed radiofrequency16, acupuncture, fire needling acupuncture, electrical nerve stimulation19, lidocaine patch, capsaicin cream, and botulinum toxin injection have been reported to give positive therapeutic effects on acute herpes zoster neuralgia (ahn), however, evidence for the efficacy of existing local therapies is limited and risks may occur due to high invasiveness of some procedures, there is insufficient evidence and expert agreement to make recommendations for these intervention strategies as first-line treatments in guidelines.

Eligibility criteria:
inclusion criteria: 1. patients with onset of hz rash less than 90 days. 2. hz affected the spinal nerves (cervical/thoracic/lumbar nerve). 3. aged 18 to 75 years (inclusive). 4. pain intensity \> 7 cm on a visual analogue scale (vas 0-10 cm). 5. agreed to sign the informed consent form. exclusion criteria: 1. infection at the puncture site. 2. poor general situation unable to be treated. 3. a history of abuse of narcotics. 4. non-compliance or inability to complete the self-evaluation questionnaires. 5. pregnancy or lactation.

Keywords: herpes zoster acute pain
belatacept conversion in proteinuric kidney transplant recipients

Conditions: Proteinuria

Summary: background: proteinuria develops in about 30% of kidney transplant recipients and is a strong predictor of graft loss. the amount of proteinuria has a direct correlation with the risk of graft failure. novel therapies are urgently needed to reduce proteinuria and prevent graft loss in transplant recipients, since ace inhibitors carry a number of limitations in the transplant setting, including significant reduction in renal function, anemia and hyperkalemia. preliminary data: b7-1 is expressed at significant levels in about 10% of kidney allograft biopsies with predominance in patients with proteinuria. hypothesis: we hypothesize that b7-1 targeting therapy may reduce proteinuria and improve graft survival in proteinuric transplant recipients that have b7-1 staining on allografts. in addition, the absence of cni nephrotoxicity and the potential protective effect of belatacept on dsa production may be of benefit in this subset of transplant patients. objectives: primary: determine the effect of belatacept conversion in reducing proteinuria by 25% at 12 months in renal transplant recipients (≥1gram/d) that are either b7-1-positive or negative on kidney biopsy. secondary: assess the effect of belatacept conversion in the percent change of renal function from baseline to 12 months; donor-specific anti-hla antibodies presence and intensity (mfi); correlation of b7-1 positivity on immunofluorescence on biopsy with b7-1-expression in urine extracellular vesicles; adverse events; acute rejection episodes; blood pressure control; new onset diabetes; hyperlipidemia; graft survival; and patient survival.

a total of 36 patients will be recruited.

Eligibility criteria:
inclusion criteria: 1. male or female adult kidney transplant recipients older than 18 years old 2. egfr ≥30 ml/min 3. ≥6 months after transplantation 4. proteinuria ≥1 gram/day in spot urine protein/creatinine ratio 5. ability to provide written informed consent for the study. 6. maintenance immunosuppression of cni (cyclosporine or tacrolimus), antiproliferative agent (azathioprine, mmf or mpa) with either steroids or not. exclusion criteria: 1. age \<18 years 2. egfr\<30 ml/min 3. active acute cellular rejection (acr; higher than borderline) or acr in the previous 6 months; active acute antibody-mediated rejection 4. recurrent fsgs 5. ebv igg negative 6. patient on mtor inhibitor (e.g. everolimus, sirolimus) 7. patient only on cni (cyclosporine or tacrolimus) and steroids

Keywords: proteinuria kidney transplantation allograft dysfunction b7-1 belatacept
biomarkers and molecular mechanism study of hepatocellular carcinoma after radical resection and conversion therapy

Conditions: Hepatocellular Carcinoma

Summary: blood samples will be tested to identify circulating tumor dna and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.


Eligibility criteria:
inclusion criteria: * patients with a first diagnosis of hcc. * patients with hcc who are to undergo surgical treatment, with or without neoadjuvant therapy. * ability to obtain tissue sample for ctdna analysis and detectable baseline ctdna level. exclusion criteria: * patients with secondary liver cancer, or intrahepatic cholangiocarcinoma. * any other concurrent malignancy. * history of organ transplant or hepatic encephalopathy.
kysa-5: a study of anti-cd19 chimeric antigen receptor t-cell (cd19 car t) therapy, in subjects with systemic sclerosis

Conditions: Systemic Sclerosis; Systemic Sclerosis - Diffuse Cutaneous; Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

Summary: a study of anti-cd19 chimeric antigen receptor t cell therapy for subjects with systemic sclerosis

ssc is an immune-mediated rheumatic disease that is characterized by fibrosis of the skin and internal organs and vasculopathy. b-cells play a role in ssc, and the disease is characterized by the presence of autoantibodies such as anti-scl-70 and anti-rnap iii antibodies. cd19-targeted chimeric antigen receptor (car) t-cells harness the ability of cytotoxic t-cells to directly and specifically lyse target cells to effectively deplete b-cells in the circulation and in lymphoid and potentially non-lymphoid tissues. kyv-101, a fully human anti-cd19 car t-cell therapy, will be investigated in adult subjects with systemic sclerosis.

Eligibility criteria:
key inclusion criteria 1. clinical diagnosis of ssc according to 2013 acr/eular classification 2. clinical disease as follows: classified as diffuse cutaneous ssc; ≤ 6 years since first non-raynaud's sign or symptom; active disease 3. up to date on all recommended vaccinations per cdc or institutional guidelines for immune-compromised individuals key exclusion criteria 1. clinically significant ild 2. prior treatment with cellular therapy (car-t) or gene therapy product directed at any target 3. history of allogeneic or autologous stem cell transplant 4. evidence of active hepatitis b or hepatitis c infection 5. positive serology for hiv 6. primary immunodeficiency 7. history of splenectomy 8. history of stroke, seizure, dementia, parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject 9. impaired cardiac function or clinically significant cardiac disease 10. previous or concurrent malignancy with the following exceptions: 1. adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening) 2. in situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening 3. a primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening

Keywords: kyv-101 systemic sclerosis autoimmune disease anti-cd19 car-t therapy cellular therapy scleroderma
the effects of three oral medications on post-operative pain following endodontic treatment

Conditions: Pulpitis; Pain Management

Summary: aim: eliminating or reducing pain following endodontic treatment is of great importance. the aim of this study is to compare the effects of tramadol, novafen and naproxen on post-operative pain following instrumentation of root canals in teeth with irreversible pulpitis. sample size: one hundred patients considering the inclusion and exclusion criteria were selected. intervention and outcome: the effect of tramadol, novafen and naproxen on post-operative pain following instrumentation of root canals in teeth with irreversible pulpitis was evaluated.


Eligibility criteria:
inclusion criteria: 1. the subjects were 20-60 years of age with no systemic diseases and females were not pregnant; 2. no history of taking any analgesics or other drugs prior to presenting for treatment; 3. patients had moderate to severe pain associated with irreversible pulpitis in single-rooted premolars or anterior teeth. exclusion criteria:

Keywords: endodontics pain visual analogue scale nsaids
stop for stress - a randomized controlled trial comparing an online and a group-based format of an intervention for work-related stress

Conditions: Work-Related Stress

Summary: work-related stress is a major public health concern, causing sickness absenteeism and impaired health and well-being. many afflicted with severe work-related stress will not receive evidence-based treatment due to geographical distance, stigma and unwillingness to participate in a group, creating unequality access to healthcare services. online interventions show comparable effects to face-to-face interventions and have potential to break down some of these barriers. we have developed and pilot tested the online delivery format of the intervention for work-related stress, stop for stress, with promising results. in a two-armed, multicentre randomized controlled trial we aim to 1) compare the effect of the online delivery format and an evidence-based face-to-face group-based format and 2) identify markers of enhanced outcomes in each delivery format. the study will include 220 patients with severe work-related stress (110 from each of two centres) who are randomizes 1:1 to the two interventions. outcomes consist of self-report measures of psychological symptoms, cognitive functioning, sleep, and perceived working environment and register data on ebsenteeism and return-to-work.


Eligibility criteria:
inclusion criteria: * current employment and significant work-related stressors * perceived stress scale (pss-10) score ≥20 and symptom duration \>4 weeks * in case of full-time sick leave, return to work must be planned concurrent with the intervention * access to a computer or tablet with internet connection at home exclusion criteria: * interpersonal difficulties, bullying, harassment, violence, threats, and traumatic events as primary stressor * severe stressors outside of work * symptoms meeting diagnostic criteria for anxiety, depression or severe psychiatric illnesses requiring specialized treatment * current abuse of alcohol and/or psychoactive drugs

Keywords: work-related stress online intervention group intervention return-to-work
mindbeacon therapist assisted internet delivered cbt for depression

Conditions: Major Depressive Disorder

Summary: utilization of therapist assisted internet-delivered cognitive behavioural therapy (taicbt) for treating depression and anxiety disorders in stepped-care models, such as the uk's improving access to psychological therapies (iapt) and the ontario structured psychotherapy program (spp), is a potential solution for addressing the treatment gap in mental health. investigators propose to investigate the effectiveness of beacon taicbt for depression to demonstrate the potential value of taicbt in a stepped care model. investigators propose to conduct a 12-week pragmatic randomized controlled trial with a 1:1 (icbt intervention: waiting-list) allocation, for participants referred to the anxiety and mood, prompt anxiety and mood, and trauma programs at ontario shores centre for mental health sciences and on a waiting-list to receive clinical service. the primary outcome measures will be the improving access to psychological therapies (iapt) definitions of recovery, reliable improvement, and reliable recovery which are derived using the phq-9 and gad-7 . the phq-9 (depression), gad-7 (anxiety) and wsas (functional impairment) will be used as secondary outcome measures for all participants. over the course of the study, 200 participants will be randomized (icbt, 100; waiting-list, 100). statistical analyses will include intention-to-treat analyses to test the interaction effects for the primary outcome measures at discharge/12-weeks and 3, and 12 months post-treatment. it is predicted that participants in the treatment condition will show significantly reduced symptoms of depression related to the waitlist control. it is predicted that this will be maintained through follow up.


Eligibility criteria:
inclusion criteria: * minimum age of 18 years * meets diagnostic assessment research tool (dart) screening criteria for a primary diagnosis of depression and reports being at least moderately depressed according to the phq-9 * sufficient language proficiency to understand the treatment materials written at grade 10 reading level * understands what taicbt and is open and interested to participating in a study using this treatment modality * is able to reliably access the internet, and has basic computer skills to navigate the internet using a web browser * willing to participate in a waitlist-control study and be followed for 12 months exclusion criteria: * suicidal intent or clinically significant suicidal ideation * clinically significant self-harm * active psychotic illness * currently participating in psychological treatment for depression and/or receiving evidence-based treatment (other than medication) for depression * clinically significant alcohol and/or other substance use including prescription and over the counter medication that would likely interfere with treatment * current or previous diagnosis of borderline personality disorder * does not meet dart criteria for a primary diagnosis of depression * change in psychotropic medication within 3 weeks of treatment baseline

Keywords: depression